Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 8/20 | 0.37 |
| ▸ | MMP2 | P08253 | 7/20 | 0.37 |
| ▸ | MMP3 | P08254 | 5/20 | 0.37 |
| ▸ | MMP9 | P14780 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174137 | 0.80 | ADAM10 (0.45) | ADAM10MMP2MMP3MMP9ERBB2 | |
| SCHEMBL2173082 | 0.80 | ALDH1A1 (0.46) | LMNAALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2176908 | 0.79 | ALDH1A1 (0.43) | LMNAALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL2173080 | 0.78 | ALDH1A1 (0.44) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2177052 | 0.77 | LMNA (0.43) | ADAM10MMP2MMP9LMNAALDH1A1 | |
| SCHEMBL2177320 | 0.76 | LMNA (0.41) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2173178 | 0.75 | LMNA (0.49) | LMNAALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL2173564 | 0.75 | LMNA (0.49) | LMNAALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL4476420 | 0.74 | GPR119 (0.39) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2174272 | 0.72 | ALOX15 (0.41) | LMNAALDH1A1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | ADAM10 25/4885MMP2 4/4885MMP3 6/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | ADAM10 26/4885MMP2 2/4885MMP3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.